Updated:
Polymerase Capital
Polymerase Capital is a venture capital firm based in Seattle, Washington, founded in 2021. It focuses on investments in life science companies.
Polymerase Capital
Polymerase Capital is a venture capital firm based in Seattle, Washington, founded in 2021. It focuses on investments in life science companies. The firm has made one investment to date.
General information
Firm type
Generalist
Year founded
2021
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Principals
Thomas Chalberg
Founder and Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Polymerase Capital?
Founder and Managing Director Thomas Chalberg, Ph.D., leads investment decisions. Chalberg is a scientist by training with operating experience as co-founder of Genascence, a gene therapy company targeting osteoarthritis. His investment decisions are informed by this deep domain expertise in molecular biology and clinical development.
Does Polymerase Capital participate in fund commitments or only direct deals?
The firm's known activity centers on direct venture investments rather than fund-of-fund commitments. Its co-investment relationships are deal-specific—partnering with entities like DeepWork Capital on Genascence—rather than LP positions in blind-pool venture funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: